{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:42:55Z","timestamp":1790628175369,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109103h0003"],"award-info":[{"award-number":["JP17ek0109103h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS","award":["19K16973"],"award-info":[{"award-number":["19K16973"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1136\/ard-2022-223645","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:08:12Z","timestamp":1678770492000},"page":"809-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance"],"prefix":"10.1016","volume":"82","author":[{"given":"Saeko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-8035","authenticated-orcid":false,"given":"Yasuo","family":"Nagafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineto","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-9309","authenticated-orcid":false,"given":"Yusuke","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakano","family":"Masahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryochi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-4039","authenticated-orcid":false,"given":"Norio","family":"Hanata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-0760","authenticated-orcid":false,"given":"Yukiko","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Shimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-1699","authenticated-orcid":false,"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-3625","authenticated-orcid":false,"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223645_bib1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib2","first-page":"1135","article-title":"Difficult-To-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223645_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","article-title":"Risk profiling for a refractory course of rheumatoid arthritis","volume":"49","author":"B\u00e9c\u00e8de","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223645_bib4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib5","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Sanayama","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223645_bib6","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","article-title":"Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial","volume":"66","author":"Sellam","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223645_bib7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-223645_bib8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-223645_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.27226","article-title":"Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta\/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort","volume":"62","author":"Mavragani","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223645_bib10","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223645_bib11","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/ar2746","article-title":"Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab","volume":"11","author":"Richez","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223645_bib12","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1182\/blood-2002-03-0671","article-title":"Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis","volume":"100","author":"Ponchel","year":"2002","journal-title":"Blood"},{"key":"10.1136\/ard-2022-223645_bib13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/annrheumdis-2015-207991","article-title":"T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals","volume":"75","author":"Hunt","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib14","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1136\/annrheumdis-2013-203566","article-title":"An immunological biomarker to predict MTX response in early RA","volume":"73","author":"Ponchel","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","article-title":"Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs","volume":"76","author":"Figueiredo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"10.1136\/ard-2022-223645_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223645_bib18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa2004114","article-title":"Rna identification of prime cells predicting rheumatoid arthritis flares","volume":"383","author":"Orange","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223645_bib19","first-page":"255","article-title":"Correlation between the immunophenotypical presentation of dendritic cells and the clinical response to anti-rheumatic treatment in rheumatoid arthritis","volume":"41","author":"B\u0103l\u0103nescu","year":"2003","journal-title":"Rom J Intern Med"},{"key":"10.1136\/ard-2022-223645_bib20","doi-asserted-by":"crossref","first-page":"eaag3009","DOI":"10.1126\/science.aag3009","article-title":"Mapping the human DC lineage through the integration of high-dimensional techniques","volume":"356","author":"See","year":"2017","journal-title":"Science"},{"key":"10.1136\/ard-2022-223645_bib21","doi-asserted-by":"crossref","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","article-title":"Single-Cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"10.1136\/ard-2022-223645_bib22","author":"G\u00fcnther"},{"key":"10.1136\/ard-2022-223645_bib23","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","article-title":"Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases [dataset] 23]","volume":"184","author":"Ota","year":"2021","journal-title":"Cell"},{"key":"10.1136\/ard-2022-223645_bib24","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/rheumatology\/kez021","article-title":"Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study","volume":"58","author":"Mori","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223645_bib25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/acr.23914","article-title":"Evaluation of response criteria in rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs","volume":"72","author":"Inoue","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223645_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib27","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.21385","article-title":"Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins","volume":"52","author":"Huizinga","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223645_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","article-title":"Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration","volume":"43","author":"Anderson","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223645_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223645_bib30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ard-2022-223645_bib31","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1038\/s41467-021-25246-7","article-title":"Single-Cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis [dataset] 31]","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-223645_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"10.1136\/ard-2022-223645_bib33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","article-title":"Transcriptional basis of mouse and human dendritic cell heterogeneity","volume":"179","author":"Brown","year":"2019","journal-title":"Cell"},{"key":"10.1136\/ard-2022-223645_bib34","first-page":"689","article-title":"The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis","volume":"17","author":"van Jaarsveld","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223645_bib35","first-page":"893","article-title":"Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis","volume":"14","author":"Westgeest","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223645_bib36","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","article-title":"The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis","volume":"43","author":"Kroot","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223645_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2474-11-187","article-title":"The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis","volume":"11","author":"Cader","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/ard-2022-223645_bib38","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223645_bib39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.11156","article-title":"Understanding the window of opportunity concept in early rheumatoid arthritis","volume":"48","author":"Boers","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223645_bib40","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping systemic lupus erythematosus heterogeneity at the single-cell level","volume":"21","author":"Nehar-Belaid","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-223645_bib41","doi-asserted-by":"crossref","first-page":"eabm9409","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2022-223645_bib42","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","article-title":"Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells","volume":"51","author":"Dutertre","year":"2019","journal-title":"Immunity"},{"key":"10.1136\/ard-2022-223645_bib43","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3389\/fimmu.2020.01716","article-title":"Differential accumulation and activation of monocyte and dendritic cell subsets in inflamed synovial fluid discriminates between juvenile idiopathic arthritis and septic arthritis","volume":"11","author":"Cren","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223645_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/jci.insight.121544","article-title":"Identification of enhanced IFN-\u03b3 signaling in polyarticular juvenile idiopathic arthritis with mass cytometry","volume":"3","author":"Throm","year":"2018","journal-title":"JCI Insight"},{"key":"10.1136\/ard-2022-223645_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1172\/jci.insight.95228","article-title":"Enriched cd141+ dcs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis","volume":"3","author":"Canavan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1136\/ard-2022-223645_bib46","doi-asserted-by":"crossref","first-page":"745226","DOI":"10.3389\/fimmu.2021.745226","article-title":"Functionally mature cd1c+ dendritic cells preferentially accumulate in the inflammatory arthritis synovium","volume":"12","author":"Canavan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223645_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1126\/sciimmunol.aaw1941","article-title":"Tissue clonality of dendritic cell subsets and emergency dcpoiesis revealed by multicolor fate mapping of DC progenitors","volume":"4","author":"Cabeza-Cabrerizo","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2022-223645_bib48","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1038\/s41467-018-05816-y","article-title":"Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function","volume":"9","author":"Laustsen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-223645_bib49","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1038\/s41467-022-31054-4","article-title":"Ly6D","volume":"13","author":"Lutz","year":"2022","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-223645_bib50","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","article-title":"The type I IFN signature as a biomarker of preclinical rheumatoid arthritis","volume":"72","author":"L\u00fcbbers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223645_bib51","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:35:26Z","timestamp":1739504126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003496724083936"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223645","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.21.22283652","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}